This post is a summary of some of my work as a field strategy consultant at Schmidt Futures' Act 2 program, where I spoke with over a hundred experts and did a deep dive into antimicrobial resistance to find impactful investment opportunities within the cause area. The full report can be accessed here.Antimicrobials, the medicines we use to fight infections, have played a foundational role in improving the length and quality of human life since penicillin and other antimicrobials were first developed in the early and mid 20th century.Antimicrobial resistance, or AMR, occurs when bacteria, viruses, fungi, and parasites evolve resistance to antimicrobials. As a result, antimicrobial medicine such as antibiotics and antifungals become ineffective and unable to fight infections in the body.AMR is responsible for millions of deaths each year, more than HIV or malaria (ARC 2022). The AMR Visualisation Tool, produced by Oxford University and IHME, visualises IHME data which finds that 1.27 million deaths per year are attributable to bacterial resistance and 4.95 million deaths per year are associated with bacterial resistance, as shown below.Source:https://forum.effectivealtruism.org/posts/W93Pt7xch7eyrkZ7f/cause-area-report-antimicrobial-resistanceNarrated for the Effective Altruism Forum by TYPE III AUDIO.Share feedback on this narration.